Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases like Parkinson's ...

From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, scientists were able to identify patterns of neurodegeneration and create metrics ...

Parkinson’s disease is a brain disorder that affects movement, making everyday tasks difficult for nearly one million people ...

Now, a new study from Renmin Hospital of Wuhan University provides strong evidence that kidney failure may also contribute to the development of Parkinson’s disease by triggering the spread of ...

Lewy body diseases (LBDs) are a class of debilitating neurodegenerative disorders linked to the abnormal aggregation of the ...

Among patients with iRBD, altered visuospatial cue-elicited N2 and P3 ERPs predicted phenoconversion to α-synucleinopathies.

A compound that showed early promise in the treatment of Parkinson's disease in fruit flies has also shown neuroprotective ...

One of the most common early signs of dementia is short-term memory loss—as is forgetting important dates or events, ...

Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

The initial topline results for the Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB) were previously disclosed ... of the underlying neurodegenerative processes that causes disease in ...

A Journey with Lewy Body Dementia has been presented in Continuing Medical Education programs offered by Kaiser Permanente and other <a ...